<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Nagaraja V</submitter><funding>NIAMS NIH HHS</funding><pagination>1944-53</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4603276</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>54(11)</volume><pubmed_abstract>SSc is a multiorgan disease with significant morbidity that is associated with poor health-related quality of life. Treatment of this condition is often organ based and non-curative. However, there are newer, potentially disease-modifying therapies available to treat certain aspects of the disease. This review focuses on old and new therapies in the management of SSc in clinical practice.</pubmed_abstract><journal>Rheumatology (Oxford, England)</journal><pubmed_title>Old medications and new targeted therapies in systemic sclerosis.</pubmed_title><pmcid>PMC4603276</pmcid><funding_grant_id>K24 AR063120</funding_grant_id><pubmed_authors>Denton CP</pubmed_authors><pubmed_authors>Khanna D</pubmed_authors><pubmed_authors>Nagaraja V</pubmed_authors></additional><is_claimable>false</is_claimable><name>Old medications and new targeted therapies in systemic sclerosis.</name><description>SSc is a multiorgan disease with significant morbidity that is associated with poor health-related quality of life. Treatment of this condition is often organ based and non-curative. However, there are newer, potentially disease-modifying therapies available to treat certain aspects of the disease. This review focuses on old and new therapies in the management of SSc in clinical practice.</description><dates><release>2015-01-01T00:00:00Z</release><publication>2015 Nov</publication><modification>2021-02-20T03:33:31Z</modification><creation>2019-03-27T01:59:58Z</creation></dates><accession>S-EPMC4603276</accession><cross_references><pubmed>25065013</pubmed><doi>10.1093/rheumatology/keu285</doi></cross_references></HashMap>